Preventing Respiratory Syncytial Virus (RSV) infection with a novel antigen-adjuvant platform

Respiratory Syncytial Virus (RSV) is the most common cause of lower respiratory tract infection in young children worldwide, and re-infections occur throughout life. In persons older than 65, those with underlying cardiac or lung disease and in the immune compromised RSV causes a serious illness like influenza. Despite this burden of illness no vaccine is currently available to prevent RSV. In this study we will test a novel RSV antigen combined with a new adjuvant (immune booster) to see if it is safe in healthy people age 50 to 64, and if they make antibodies to the vaccine. If the vaccine is safe and antibodies are made, the RSV vaccine would have the potential to be a future vaccine to prevent this common infection.